Skip to main content

Advertisement

SpringerLink
Log in

Polycomb group protein Bmi1 expression in colon cancers predicts the survival

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Colorectal cancer is the second leading cause of cancer-related death in the United States and the fourth leading cause worldwide. Currently, there is still no excellent predictor of the survival. Polycomb-group proteins Bmi1 is regarded as a “stemness” gene involved in the maintenance of stem cells, malignant transformation, and biologic aggressiveness of several human carcinomas. We examined the expression of the Bmi1 in colon cancer and its relevance to other characteristics, especially the 5-year survival of colon cancer. The expression of Bmi1 was examined in colorectal carcinoma (n = 98) by using real-time polymerase chain reaction. Expression was correlated with clinicopathologic variables, 5-year overall survival (OS) rates. We for the first time found that high expression of Bmi1 was significantly associated with poor survival. Fourfold Table Chi-square Test analysis revealed that Bmi1 expression was closely related to TNM stage and histologic grade, while not relevant to age. In summary, the high expression of polycomb-group protein Bmi1 is an essential and important predictor of colorectal cancer prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.

    Article  PubMed  Google Scholar 

  2. van der Lugt NM, Domen J, Linders K, van Roon M, Robanus-Maandag E, te Riele H, et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 1994;8:757–69.

    Article  PubMed  Google Scholar 

  3. Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J Clin Invest. 2004;113:175–9.

    CAS  PubMed  Google Scholar 

  4. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397(6715):164–8.

    Article  CAS  PubMed  Google Scholar 

  5. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol. 2007;18(5):460–6.

    Article  CAS  PubMed  Google Scholar 

  6. Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci. 2009;29(28):8884–96.

    Article  CAS  PubMed  Google Scholar 

  7. Martínez-Romero C, Rooman I, Skoudy A, Guerra C, Molero X, González A, et al. The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol. 2009;219(2):205–13.

    Article  PubMed  CAS  Google Scholar 

  8. Hoenerhoff MJ, Chu I, Barkan D, Liu ZY, Datta S, Dimri GP, et al. BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene. 2009;28(34):3022–32.

    Article  CAS  PubMed  Google Scholar 

  9. Tateishi K, Ohta M, Kanai F, Guleng B, Tanaka Y, Asaoka Y, et al. Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract. Clin Cancer Res. 2006;12(23):6960–6.

    Article  CAS  PubMed  Google Scholar 

  10. Chiba T, Miyagi S, Saraya A, Aoki R, Seki A, Morita Y, et al. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res. 2008;68(19):7742–9.

    Article  CAS  PubMed  Google Scholar 

  11. Piscaglia AC. Stem cells, a two-edged sword: risks and potentials of regenerative medicine. World J Gastroenterol. 2008;14(27):4273–9.

    Article  PubMed  Google Scholar 

  12. Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer. 2009;125(10):2323–31.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded by National Science Foundation of China NSFC: No.30471698.

Author information

Authors and Affiliations

  1. Department of Gastroenterology Surgery, Xijing Digestive Hospital, The Fourth Military Medical University, Xi’an, Shaanxi Province, People’s Republic of China

    Yongqi Li, Jipeng Li & Jianyong Zheng

  2. Changlexi Road No. 15th, Xi’an, Shaanxi Province, People’s Republic of China

    Jianjun Du

Authors
  1. Jianjun Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yongqi Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jipeng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jianyong Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianjun Du.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Du, J., Li, Y., Li, J. et al. Polycomb group protein Bmi1 expression in colon cancers predicts the survival. Med Oncol 27, 1273–1276 (2010). https://doi.org/10.1007/s12032-009-9373-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-009-9373-y

Keywords

Search

Navigation